A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...

Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate. See why ABVX stock is a Buy.

Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM ESTCompany ParticipantsJohn Quisel - CEO, President ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian ...

The Vitiligo market presents opportunities through 18+ companies developing 20+ pipeline drugs, with a focus on novel approaches. Key phases include Phase III (Afamelanotide), Phase II (VYN201), and ...

Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –– ...

The Phase 2b ADAPTIVE trial is a randomized, placebo-controlled dose-finding study designed to evaluate the efficacy and safety of various dose regimens of IMG-007 in adults with moderate-to-severe AD ...

Following the FDA approval of a vagus nerve stimulator for rheumatoid arthritis, supporters of the device’s use have lauded ...

Incyte today announced the expansion of its Moments of Clarity program, which amplifies the voices of people living with chronic immune-mediated skin conditions. This year, the initiative introduces ...

Phase 3 PEAK results in 2 nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug ...

RESEARCH presented at UEG Week 2025 revealed how Westernised diets, which are rich in fat and sugar but low in fibre, can ...